Available survival data suggested differences between the three groups of mesenchymal tumors with DICER1 alteration, with a significantly better progression free survival for LGMT DICER1 when compared to SARC DICER1 and PIS DICER1 (Fig. 2d–f). The gene discussed is DICER1; the disease is mesenchymal cell neoplasm.